dc.contributor.author | Dufek, M. | |
dc.contributor.author | Dawson, K. | |
dc.contributor.author | Meluzinova, E. | |
dc.contributor.author | Yang, M. | |
dc.contributor.author | O'Neill, G. N. | |
dc.contributor.author | Eraksoy, M. | |
dc.contributor.author | MacManus, D. G. | |
dc.contributor.author | Miller, D. H. | |
dc.contributor.author | Kappos, L. | |
dc.contributor.author | Gold, R. | |
dc.contributor.author | Havrdova, E. | |
dc.contributor.author | Limmroth, V. | |
dc.contributor.author | Polman, C. H. | |
dc.contributor.author | Schmierer, K. | |
dc.contributor.author | Yousry, T. A. | |
dc.date.accessioned | 2021-03-05T18:59:25Z | |
dc.date.available | 2021-03-05T18:59:25Z | |
dc.date.issued | 2011 | |
dc.identifier.citation | MacManus D. G. , Miller D. H. , Kappos L., Gold R., Havrdova E., Limmroth V., Polman C. H. , Schmierer K., Yousry T. A. , Eraksoy M., et al., "BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis", JOURNAL OF NEUROLOGY, cilt.258, ss.449-456, 2011 | |
dc.identifier.issn | 0340-5354 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_cd0ac2c9-768a-4460-a746-85a167a02f31 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/135724 | |
dc.identifier.uri | https://doi.org/10.1007/s00415-010-5777-z | |
dc.description.abstract | BG-12, an immunomodulatory agent, reduces frequency of new gadolinium-enhancing (Gd+) lesions in relapsing multiple sclerosis (MS). This study reports the effect of 240 mg BG-12 orally three times daily (tid) for 24 weeks on the evolution of new Gd+ lesions to T1-hypointense lesions. Brain magnetic resonance imaging (MRI) scans from patients in placebo and 240 mg BG-12 tid arms of a phase 2b study were examined retrospectively. Included patients had at least one new Gd+ lesion from weeks 4 to 12. Week 24 scans were analyzed for number and proportion of new Gd+ lesions that evolved to T1-hypointense lesions. Eighteen patients receiving BG-12 and 38 patients receiving placebo were included in the analysis. The analysis tracked 147 new Gd+ lesions in patients from the BG-12 group and 221 Gd+ lesions in patients from the placebo group. The percentage of Gd+ lesions that evolved to T1-hypointense lesions was 34% lower with BG-12 treatment versus placebo (29%, BG-12; 44%, placebo; odds ratio 0.51; 95% confidence interval 0.43, 0.61; p < 0.0001). In addition to reducing frequency of new Gd+ lesions, BG-12 significantly reduced probability of their evolution to T1-hypointense lesions in patients with MS compared with placebo. | |
dc.language.iso | eng | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Nöroloji | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | KLİNİK NEUROLOJİ | |
dc.title | BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis | |
dc.type | Makale | |
dc.relation.journal | JOURNAL OF NEUROLOGY | |
dc.contributor.department | İstanbul Üniversitesi , , | |
dc.identifier.volume | 258 | |
dc.identifier.issue | 3 | |
dc.identifier.startpage | 449 | |
dc.identifier.endpage | 456 | |
dc.contributor.firstauthorID | 199819 | |